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Abstract: Many of the infectious diseases that affect livestock have bacteria as etiological agents.
Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching
the environment through slurry and waste water. Once there, antimicrobial residues may lead
to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective
was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate
molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine,
oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed
via LC-MS/MS. Oxytetracycline had the slowest rate of degradation (a half-life time of 4.18 days) and
the most extended elimination period in urine (over 2 months), followed by enrofloxacin (a half-life
time of 1.48 days, total urine elimination in ca. 3 weeks) and sulfamethoxypyridazine (a half-life time
of 0.49 days, total urine elimination in ca. 1 week). Bacterial sensitivity and recommendations for
responsible use are limiting when selecting the treatment. Nevertheless, with similar effectiveness,
sulfamethoxypyridazine would be the choice, as waste treatment would only need to be implemented
for 1 week after treatment. Thus, more in-depth knowledge regarding antibacterial elimination would
improve resource management, while protecting animals and consumers’ health.
Keywords: antibiotic; sulfonamide; quinolone; excretion; LC–MS/MS; urine
1. Introduction
Antimicrobials are compounds administered to livestock for a number of reasons. On
the one hand, they have traditionally been administered for non-therapeutic purposes,
including disease prophylaxis and growth promotion [1,2]; on the other hand, they can
be dispensed to treat diseases when they emerge. The diversity of uses for antimicrobials
in farm breeding has led to an increased worldwide demand for antibiotics in livestock
production which has even surpassed the total amount of human consumption [3]. As a
consequence, it is now encouraged to rationalize their use [4,5]. Furthermore, the EMA
(European Medicines Agency) has issued recommendations regarding their order of el-
igibility [6]. Indeed, growth promoters have been banned in the European Union since
2006, and prophylaxis is now likewise restricted in some animal groups (Regulation (EU)
2019/4 [7] and Regulation (EU) 2019/6 [8]). Nevertheless, the severity of some illnesses
still requires treatment with antimicrobials.
Ideally, disease management would involve an accurate diagnosis of the causal agent
involved, through the collection of an accurate sample for bacterial culture and antimi-
crobial susceptibility testing. Nonetheless, susceptibility is not the only feature to be
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considered, as certain antimicrobials are limited to human use [6], and the mode of ad-
ministration of certain other antimicrobials might not be feasible on each type of farm.
After administration, antimicrobials spread throughout the animal’s organism, reaching
most of its tissues. Nevertheless, the degree of concentration in each organ depends on
the antibiotic’s pharmacokinetics as well as the moment of treatment. Once the compound
has fulfilled its function, it leaves the tissues and is excreted through several pathways, of
which urine is one of the most predominant [9–13].
Although antimicrobial therapy significantly reduces economic loss and mortality
rates on farms, antimicrobial residues produce a considerable array of negative side effects
when they are released to the environment. On the one hand, antimicrobial residues exert
a series of potential long-term adverse effects on humans and animals [14–17]. On the
other, such deposits wield an intense pressure towards the genetic selection of resistant
bacteria [18,19]. Although direct damage on human health is the most visible consequence,
the development of resistant bacteria populations is the most severe side effect, as antimi-
crobials become useless against common illnesses easily addressed before. So severe is this
problem that, by the year 2050, antimicrobial resistance generation (AMR) is estimated to
be causing 10 million deceases per year overpassing illnesses such as cancer [4].
Several studies have set out to determine the amount of antimicrobial residues in
manure and slurry and have found concentrations as high as 20,000 µg kg−1 of sulfonamide
in Switzerland [20], 43 µg kg−1 of tiamulin in Germany [21], and 31 different antibiotic
residues in China, with concentrations of sulfamethazine exceeding 5650 µg kg−1 [22]. Ma-
nure and slurry are usually used as natural fertilizers in agriculture, thereby dramatically
spreading antibacterial residues in nature [23,24]. They are washed from the soil by rainwa-
ter, with the possibility of reaching nearby streams [25–27]. The United States Geological
Survey (USGS) recovered 21 different antibiotics from watercourses in 1999–2000 [28].
Once these compounds have reached the environment, it is no longer feasible to
eliminate them because some of them are not biodegradable [29]. The best way to manage
them is by their destruction before they leave the farm. Several methods are being studied
to avoid antibiotic release, such as heating [30,31], sorption of antibiotics onto carbona-
ceous materials [18], anaerobic digestion [32,33], manure composting [34,35], solid-liquid
separation [36], and Fenton reaction [37]. These procedures involve a series of technologies,
the choice of which will be dependent on the antimicrobial used and the concentration
excreted, which, in turn, will depend on the moment of therapy. Moreover, an antimicrobial
will be chosen for its effectiveness and for its compliance with European recommendations.
Hence, this study’s objective is to describe the rate of antimicrobial excretion in urine after
treatment with a series of different antimicrobials (a tetracycline, a sulfonamide, and a
quinolone) in order to suggest which is the most appropriate molecule for therapeuti-
cal treatment, thereby guaranteeing a successful therapy along with the most thorough
elimination of antimicrobial residues, to ensure sustainable resource management.
2. Results and Discussion
Antibacterial therapy is widespread and goes hand in hand with our current welfare
state and economic development. Once antibiotics exert their effect, urine has been demon-
strated to be the main path of elimination of most of their residues. Unexpected delivery
of these compounds to external areas such as farm surroundings or the food chain [21]
might exacerbate the serious problem of the emergence of AMR. One of the easiest ways
of limiting the entrance of antibacterial compounds into the environment is by treating
animal wastes before their removal from farm facilities [38]. Thus, better knowledge on the
subject of antimicrobial elimination would rationalize production thanks to better resource
management in waste treatment and by helping producers to choose the most suitable
antibacterial treatment. A detailed study of the excretion rates of antimicrobials via urine
would represent a first step in helping to make the best decisions when planning waste
management. Thus, as a first step, 62 pigs were treated with several antimicrobials currently
used in livestock farming (sulfamethoxypyridazine, oxytetracycline, and enrofloxacin).
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After collection, urine samples were analysed using LC-MS/MS within the first month,
as certain antimicrobials might otherwise soon have degraded [39,40]. Novel extraction
procedures and analysis techniques were developed in order to perform accurate analysis.
2.1. Excretion of Sulfamethoxypyridazine via Urine
Sulfamethoxypyridazine is a bacteriostatic compound from the sulfonamide family
which, once administrated, spreads widely throughout the body. After attaining thera-
peutic concentrations in the bloodstream and having reached body tissues, it is mainly
excreted through the kidneys, although it can be excreted to a lesser extent via fluids
other than urine [41]. It can be classified as a long-acting sulfonamide, which is why the
withdrawal period of sulfamethoxypyridazine-based drugs for food-producing animals is
quite extended (Table 1).
Table 1. Half-lives of elimination (T1/2) calculated using Equation (1) and estimated times for
the complete removal from urine determined for sulfamethoxypyridazine, oxytetracycline, and
enrofloxacin expressed in days.
Antibacterial Molecule Slope 1 R2 2 λz T1/2
Estimated Time for
Complete Excretion
Sulfamethoxypyridazine 0.6144 ± 0.1052 0.99 0.71 0.49 6.89
Oxytetracycline 0.07194 ± 0.015 0.64 6.04 4.18 63.38
Enrofloxacin 0.2027 ± 0.0760 0.47 2.14 1.48 20.48
1 R2 coefficient describes the goodness of the fit found for the occurrence of the antimicrobial´s removal by urine.
2 λZ: rate of elimination.
Figure 1 shows the occurrence of sulfamethoxypyridazine concentration in urine
through the withdrawal period. As expected, this compound was present in higher concen-
trations within the first days, decreasing at an exponential rate as the withdrawal period
progressed until reaching concentrations that approached the LoD of the chromatographic
technique. The decrease of sulfamethoxypyridazine in urine to levels as low as the LoD
(10 ppb) ensures almost complete excretion. From these data, and according to Equation (1),
this is equivalent to a half-life time of 0.49 days (Table 1).
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Figure 1. Occurrence of the concentration of sulfamethoxypyridazine in urine samples obtained
from pigs treated with sulfamethoxypyridazine at pre-set intervals within the withdrawal period
(when day 0 m tches the end of the treatment), determined via liquid chromatography with tand m
mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical
technique for sulfamethoxypyridazine.
Figure 1 also displays somewhat wide variations among the elimination rates in indi-
vidual animal specimens. Although this variability between animals subjected to the same
Antibiotics 2021, 10, 762 4 of 14
treatment and withdrawal period could be viewed as large (as reflected in the R2 values of
the regression (Table 1)), differences between rates of removal are ascribable to individual
variations. These pharmacokinetic differences are also consistent with the ones previ-
ously described for other antimicrobials such as macrolides [42] or even for sulfonamide
pharmacokinetics after treatment via either oral [43] or intravenous administration [44].
According to the regression carried out, the time period required to complete the ex-
cretion of sulfamethoxypyridazine by urine could be estimated at almost a week (Table 1).
Although sulfamethoxypyridazine is rapidly eliminated, this antimicrobial family is nev-
ertheless commonly found in high levels in farm wastes [45], and thus, waste treatments
are required for at least seven days after the end of treatment, and their features will be
dependent on the concentration of the excreted sulfonamide.
2.2. Excretion of Oxytetracycline via Urine
Oxytetracycline is commonly administered via intramuscular injection and usually has
long-lasting formulations: the drug is slowly released through the body over a prolonged
period of time, and this behaviour is reflected in certain studies which detected long
mean residence times [46], which correspond with the extended withdrawal period set
by manufacturers for commercial oxytetracycline-based products (Table 1). Regarding its
excretion pathways, 60% of the antibiotic administered in the treatment is excreted in urine
via glomerular filtration, while the remaining 40% is eliminated in the faeces [9].
Figure 2 shows the occurrence of oxytetracycline concentration in urine through the
withdrawal period. It shows that the antimicrobial concentration in urine decreased as the
withdrawal period progressed, and the compound was depleted following an exponential
rate. Once more, certain notable differences between the rates of excretion of oxytetracycline
via urine in animals subjected to the same treatment and withdrawal period might be
related to individual characteristics. Although certain variations in the concentrations can
be observed, such differences in oxytetracycline pharmacokinetics have been previously
described [47].
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Figure 2. Occurrence of the concentration of oxytetracycline in urine samples obtained from pigs
treated with oxytetracycline at pre-set i tervals within the withdrawal period (when day 0 matches
the end of the treatment), determined by liquid chromatography with tandem mass spectrometry
(LC-MS/MS). Th LoD dotte line repr sents the dete tion limit of the analytical technique for
oxytetracycline.
The half-life time calculated using Equation (1) for oxytetracycline in urine was
4.18 days (Equation (1), Table 1). Considering the compound’s high initial concentration,
and extrapolating from the regression calculating the time required for the entire excretion
of the antimicrobial from urine, more than two months would be needed to attain a
complete excretion, a much longer period when compared to the end of the withdrawal
period set by the manufacturer (28 days). This could be one of the reasons why this
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antimicrobial family is frequently detected at high levels in farm wastes [48], along with
the fact that waste treatments are often either poor or non-existent. Tetracyclines have
indeed been detected in groundwaters and lagoons in the vicinity of swine production
facilities [49–51].
2.3. Excretion of Enrofloxacin via Urine
Enrofloxacin absorption is nearly complete after intramuscular administration, but to a
great extent it is metabolized to ciprofloxacin. This is the reason why both compounds need
to be explored via analysis. Enrofloxacin is mainly excreted via urine, with concentrations
several times higher than in blood plasma; only slight amounts appear in faeces [10].
Enrofloxacin concentrations described in urine through the withdrawal period are
presented in Figure 3. As with the other two antibacterial compounds, enrofloxacin
concentrations declined as the withdrawal period progressed, and concentration decrease
was an exponential function of time. From the regression over the data obtained, the
compound’s half-life time was found to be 1.48 days (Table 1).
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Figure 3. Occurrence of the concentration of enrofloxacin in urine samples obtained from pigs treated
with enrofloxacin at pr -set intervals within the withdrawal period (when day 0 matches the end of
the treatment), determined via liquid chroma ography tandem mass spectrometry (LC-MS/MS).
Th LoD dott d line represents th detection l mit of the analytic l technique for enrofloxacin.
Apart from half-life times, Table 1 shows the regression’s goodness of fit. Once again,
a low R2 value was found, as differences could be observed between the concentrations
described in different animals subjected to the same treatment and withdrawal period.
Nonetheless, such divergences have been previously demonstrated for other antimicrobials
and drugs in g ner l. In particular, di fer es in enrofloxacin metabolization have b en
previously described in plasma after oral [52] and subcutaneous [53] administration in pigs.
The regression also allowed us to estimate the time period after the end of treat-
ment for the complete excretion of enrofloxacin: almost three weeks. As occurred with
oxytetracycline, pigs would actually continue excreting enrofloxacin long after the end
of the withdrawal period set by the manufacture (12 days). This means that although
antimicrobials might have been removed from muscle, they are still being disseminated by
previously treated animals and should be taken into consideration in terms of farm waste
management.
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2.4. Comparative Study
Urine samples were obtained in parallel with muscle and blood samples gathered for
the study performed by Serrano et al. [54]. That study’s aim was to find a suitable matrix
for ante mortem tests for the detection of antimicrobial compounds, which would avoid the
slaughter of contaminated animals and thus the entrance of antimicrobial compounds into
the food chain. The matrix should be characterized via an easy extraction procedure from
living animals and a good correlation with the concentration found in muscle. Whilst blood
proved to fulfil both requirements [54], urine results obtained in the present study showed
that urine is not a suitable matrix for that purpose (Figure 4). These findings agree with
those described previously by Seymour et al. [55] for cows: urine samples from treated
cows tested positive for the presence of antimicrobial residues even after the end of the
withdrawal period set by the manufacturer. Moreover, this issue could also be interpreted
as the occurrence of higher levels of antimicrobials in urine compared to other tissues such
as muscle.
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Figure 4. Relationship among the concentrations of sulfamethoxypyridazine (a), oxytetracycline (b),
and enrofloxacin (c) detected in muscle and urine samples. The bisecting dotted line represents the
1:1 correlation if both matrixes contained the same concentration of enrofloxacin.
Figure 4 describes the correlation between the concentration of sulfamethoxypyry-
dazine (Figure 4a), oxytetracycline (Figure 4b), and enrofloxacin (Figure 4c) in muscle and
urine. With the exception of sulfamethoxypyrydazine, concentrations described in urine
were much higher than the ones described for muscle. This indicates that antibiotics might
be eliminated for periods of time longer than those required by the European maximum
residue limits for muscle [56]. Hig r concentrations in urine compared to mus le are
common and have been previously described for several antimicr bials such as oxytetracy-
cline, florfenicol, tylosin, sulfadiazine, trimetropim, and enrofloxacin in food-producing
swine [13].
Although the high concentrations described in urine open up new possibilities for
urine applications in the field of detection tests for anti icrobial residues (for instance,
to detect illegal treatments or to ensure that a production system remains free of antibi-
otics), they also point to the imperative need of controlling farm residues, as most of the
antimicrobials removed by urine remain unaltered or are transformed into metabolites of
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the administered compound [49,50]. Antimicrobials used in this study are between the
most commonly used in Europe and are included in novel studies about soil vulnerabil-
ity to antibiotic contamination [57]. Fertilization of fields with manure and slurry could
spread these residues to the fields close to farms when fertilizing them. This practice is
increasingly considered a concern [58], mainly due to the impact on natural microbial
communities [58–60] and the potential spread of antibiotic resistant bacteria and antibiotic
resistance genes [58,61]. Moreover, antimicrobial residues reach surface waters and ground-
water by means of leaching [62], reaching distant areas and even water used by industry or
for human supply. In an attempt to tackle this problem, the EMA has developed a guideline
on environmental impact assessment of new veterinary pharmaceuticals [63]. This guide
proposes that the estimation of the total release of antimicrobials is used as the key to
assess their safety, following a similar philosophy as the one performed in the current study.
Nonetheless, good management of slurry is essential in order to deal with the problem
of uncontrolled antimicrobial delivery, but as not all the antimicrobials present the same
elimination rates, a good knowledge on the subject of their excretion is thus required to
improve waste treatment.
Referring back to antimicrobial excretion, the concentration in urine followed an
exponential rate of elimination regardless of the antimicrobial tested (Figure 5). Neverthe-
less, among compounds, depletion rates differed (p < 0.05), and thus the concentrations
measured each day differed as well. The highest concentrations at the beginning of the
withdrawal period were described for oxytetracycline (data obtained from the regression).
This circumstance, along with the slowest rate of removal described in this study (half-life
of 4.18 days, Table 1), indicates that this compound might be a problematic antibacterial
residue in terms of farm waste management.
Antibiotics 2021, 10, x FOR PEER REVIEW 7 of 14 
 
they also point to the imperative need of controlling farm residues, as most of the antimi-
crobials removed by urine remain unaltered or are transformed into metabolites of the 
administered compound [49,50]. Antimicrobials used in this study are between the most 
commonly used in Europe and are included in novel studies about soil vulnerability to 
antibiotic contamination [57]. Fertilization of fields with manure and slurry could spread 
these residues to the fields close to farms when fertilizing them. This practice is increas-
ingly considered a concern [58], mainly due to the impact on natural microbial communi-
ties [58–60] and the potential spread of antibiotic resistant bacteria a d antibiotic re-
sistance genes [58,61]. Moreover, antimicr bial r sidues reach surface waters and ground-
water by means of leaching [62], reaching distant areas and even water used by industry 
or for human supply. In an attempt to tackle this problem, the EMA has developed a 
guideline on environmental impact assessment of new veterinary pharmaceuticals [63]. 
This guide proposes that the estimation of the total release of antimicrobials is used as the 
key to asse s their s fety, following a similar philosophy as the one performed in the cur-
rent study. Nonetheless, good manag men  of slurry is essenti l in order to deal with the 
problem of uncontrolled antimicrobial delivery, but as not all the antimicrobials present 
the same elimination rates, a good knowledge on the subject of their excretion is thus re-
quired to improve waste treatment. 
Referring back to antimicrobial excretion, the concentration in urine followed an ex-
ponential r te of elimination regardless of the antimicrobial tested (Figure 5). Neverthe-
less, among compounds, depletion rates differed (p < 0.05), and thus the concentrations 
measured each day differed as well. The highest concentrations at the beginning of the 
withdrawal period were described for oxytetracycline (data obtained from the regres-
sion). This circumstance, along with the slowest rate of removal described in this study 
(half-life of 4.18 days, Table 1), indicates that this compoun  might be a problematic anti-
bacterial re idue in terms of farm waste management. 
 
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyr-
idazine (▲), oxytetracycline (), and enrofloxacin () in urine after animal treatment within the 
withdrawal period. The LoD dotted line represents the detection limit of the analytical technique 
for sulfamethoxypyridazine, oxytetracycline, and enrofloxacin. 
Enrofloxacin had a half-life of 1.48 days and sulfamethoxypyridazine of 0.49 days 
(Table 1). Thus, considering the extended half-life of oxytetracycline, urine removal rates 
described by these antimicrobials differed by up to nearly 10 times. Good knowledge re-
garding their excretion is thus critical in order to avoid uncontrolled delivery of antibac-
terial compounds to a farm’s surroundings. 
As defined by the European Medicine Agency [6], sulfonamides and tetracyclynes 
belong to category D in the classification of antibiotic classes for veterinary use, which 
means that they should be the first treatment choice. Meanwhile, enrofloxacin pertains to 
category B; it is of major relevance in human medicine and should be used only when no 
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyri-
dazine (
Antibiotics 2021, 10, x FOR PEER REVIEW 7 of 14 
 
they also point to the imper tive eed of controlling farm residues, as most of th  antimi-
robials removed by urine emain unaltered or are transformed i to metabolites of the 
administered compound [49,50]. Antimicrobials used in this study are between the most 
commonly used in Europe and are included in novel studies about soil vulnerability to 
antibiotic contamination [57]. Fertilization of fields with manure and slurry could spread 
these residues to the fields close to farms when fertilizing them. This practice is increas-
ingly considered a concern [58], mainly due to the impact on natural microbial communi-
ties [58–60] and the potential spread of antibiotic resistant bacteria and antibiotic re-
sist nce genes [58,61]. Moreover, antimi robial residues r ach surface waters and ground-
water by mea s of le ching [62], reaching distant areas and even water used by industry 
or for human supply. In an attempt to tackle this problem, the EMA has developed a 
guideline on environmental impact assessment of new veterinary pharmaceuticals [63]. 
This guide proposes that the estimation of the total release of antimicrobials is used as the 
key to assess their safety, following a similar philosophy as the one performed in the cur-
rent study. Nonetheless, good management of slurry is essential in order to deal with the 
problem of uncontrolled antimicrobial elivery, but as not all the antimicrobials present 
the same elimination r tes, a good knowledge on the subject of their excretion is thus re-
quired to impr ve waste treatment. 
Referring back to antimicrobial excretion, the concentration in urine followed an ex-
ponential rate of elimination regardless of the antimicrobial tested (Figure 5). Neverthe-
less, among compounds, depletion rates differed (p < 0.05), and thus the concentrations 
measured each day differed as well. The highest concentrations at the beginning of the 
withdrawal period were described for oxytetracycline (data obtained from the regres-
sion). This circumst nce, along with the slowest rate of rem l escribed in this study 
(half-life of 4.18 d ys, Table 1), indica es that this compound t be a problematic anti-
bacterial residue in terms of farm waste management. 
 
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyr-
idazine ( 
▲ 
), oxytetracyclin ( 
 
), and enrofloxacin ( 
 
) in urine after animal treatment within the withdrawal period. The LoD dotted line represents the 
detection limit of the analytical techn que for sulfamethoxypyridazine, oxytetracycline, and en-
rofloxacin. 
), oxytetracycline (
Antibiotics 2021, 10, x FOR PEER REVIEW 7 of 14 
 
they also point to the imperative need of controlling farm residues, as most of the antimi-
crobials removed by urine remain unaltered or are transformed into metabolites of the 
administered comp und [49,50]. An imicrobials us d in this study are between the most 
commonly used in Europe and are included in novel studies about soil vulnerability to 
antibiotic contamination [57]. Fertilization of fields with manure and slurry could spread 
these residues to the fields close to farms when fertilizing them. This practice is increas-
ingly considered a concern [58], mainly due to the impact on natural microbial communi-
ties [58–60] and the potential spread of antibiotic resistant bacteria and antibiotic re-
sistance gen s [58,61]. More r, antimicrobial resid es re ch surface waters and ground-
water by means of leaching [62], reachi g dist nt are s and even water used by industry 
or for hum n supply. In a  attempt to tackle this problem, the EMA has developed a 
guideline on environmental impact ssessment of new veterinary pharmaceuticals [63]. 
This guide proposes that the estimation of the total release of antimicrobials is used as the 
key to assess their safety, following a similar philosophy as the one performed in the cur-
rent study. Nonetheless, good management of slurry is essential in order to deal with the 
problem of uncontrolled antimicrobial delivery, but as not all the antimicrobials present 
the sa e elimination rates, a good knowledge on the subject of their excretion is thus re-
quired to improve waste treatment. 
Referring back to antimicrobial excretion, the concentration in urine followed an ex-
ponential rate of elimination regardless of the antimicrobial tested (Figure 5). Neverthe-
less, among compounds, depletion rates differed (p < 0.05), and thus the concentrations 
measured each day differed as well. The highest concentrations at the beginning of the 
withdrawal period were described for oxytetracycline (data obtained from the regres-
sion). This circumstance, along with the slowest rate of removal described in this study 
(half-life of 4.18 days, Table 1), i dicates that this compound might be a problematic anti-
bacterial residue in terms of farm waste managem nt. 
 
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyr-
idazine ( 
▲ 
), oxytetracycline ( 
 
), and enrofloxacin ( 
 
) in urine after animal treatment within the withdrawal period. The LoD dotted line represents the 
detection limit of the analytical technique for sulfamethoxypyridazine, oxytetracycline, and en-
rofloxacin.
), and enrofloxacin (
Antibiotics 2021, 10, x FOR PEER REVIEW 7 of 14 
 
they also point to the imperative need of controlling farm residues, as most of the antimi-
crobials removed by urine remain unaltered or are transformed into metabolites of the 
administered compound [49,50]. Antimicrobials used in this study are between the most 
commonly used in Europe and are included in novel studies about soil vulnerability to 
antibiotic contamination [57]. Fertilization of fields with manure and slurry could spread 
these residues to the fields close to farms when fertilizing them. This practice is increas-
ingly considered a concern [58], mainly due to the impact on natural microbial communi-
ties [58–60] and the potential spread of antibiotic resistant bacteria and antibiotic re-
sistance genes [58,61]. Moreover, antimicrobial residues reach surface waters and ground-
water by means of leaching [62], eaching distant reas and even water used by industry 
or for hu an supply. In an attempt to tackle this problem, the EMA has developed a 
guideline on environmental impact assessment of new veterinary pharmaceuticals [63]. 
This guide proposes that the estimation of the total release of antimicrobials is used as the 
key to assess their safety, following a similar philosophy as the one performed in the cur-
rent study. Nonetheless, good management of slurry is essential in order to deal with the 
problem of uncontrolled antimicrobial delivery, but as not all the antimicrobials present 
th  same elimination rates, a good knowledge on the subject of their excretion is thus re-
quired to improve w ste treatment. 
Referring back to antimicrobial excretion, the concentration in urine followed an ex-
ponential rate of elimination regardless of the antimicrobial tested (Figure 5). Neverthe-
less, among compounds, depletion rates differed (p < 0.05), and thus the concentrations 
measured each day differed as well. The highest concentrations at the beginning of the 
withdrawal period were described for oxytetracycline (data obtained from the regres-
sion). This circumstance, along with the slowest rate of removal described in this study 
(half-life of 4.18 days, Table 1), dicates that this compound might be a problematic anti-
bacterial residue in terms of farm waste management. 
 
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyr-
idazine ( 
▲ 
), oxytetracycline ( 
 
), and enrofloxacin ( 
 
) in urine after animal treatment within the withdrawal period. The LoD dotted line represents the 
etecti n limit of the analytical technique for sulfamethoxypyridazine, oxytetracycline, and en-
rofloxacin. 
) in urine after animal treatment within the
withdrawal period. The LoD dotted line represents the detection limit of the analytical technique for
sulfamethoxypyridazine, oxytetracycline, and enrofloxacin.
Enrofloxacin had a half-life of 1.48 days and sulfamethoxypyridazine of 0.49 days
(Table 1). Thus, considering the ext nded half-life of oxytetracycline, urine removal rates
described by these antimicrobials differed by up to nearly 10 times. Good knowledge
regarding their excretion is thus critical in order to avoid uncontrolled delivery of antibac-
terial compounds to a farm’s surroundings.
As defined by the European Medicine Agency [6], sulfonamides an tetracyclynes
belong to category D in the classification of antibiotic classes for veterinary use, which
mean that th y should be the first treatment choice. Meanwhile, enrofloxacin pertains
to categ ry B; it is of major relevance in human medic ne and should be used only when
no equivalently effective antimicrobials in categories C or D can be found. These con-
siderations are nevertheless restricted to the EMA’s actual recommendations regarding
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a responsible use of antimicrobials, designed to encourage veterinarians to carry out an
antibiogram before prescribing an antimicrobial treatment.
Thus, in the case of equal sensitivity to the antimicrobials studied, sulfamethoxypyry-
dazine and oxytetracycline would be the treatments to suggest. In terms of waste man-
agement and in view of the data presented in this study, sulfamethoxypyridazine would
be the ideal one of the two, as it is more rapidly eliminated in urine. This fast excretion
rate implies short periods of extra waste treatment, leading to energetic reduction and eco-
nomic savings while minimizing the delivery of antibacterial residues to the environment.
However, the increase in antimicrobial resistances investigated in recent years [64] and the
widespread description of sulfonamide resistance in different niches such as wastewaters,
sewage, aquaculture, compost, and even the meat food supply chain [65–67] might make
these compounds useless against an outbreak etiological agent [68,69], thus making it
necessary to give preference to another antibiotic instead. In case such a situation arises,
and for purposes of responsible waste management, the sequence of selection would be
proportional to the rate of removal: antimicrobials with faster rates of removal would be
the therapeutics of choice.
3. Materials and Methods
3.1. Urine Samples
3.1.1. Antimicrobials
The antimicrobials selected for animal treatment were sulfamethoxypyridazine (a
sulfonamide), oxytetracycline (a tetracycline), and enrofloxacin (a quinolone) as they are
among the most widely used antimicrobials in EU farming production; they follow different
metabolic pathways [70], and they are all effective against a wide range of bacteria. Each of
these compounds was administered via intramuscular (IM) injection. Table 2 shows the
main features of the antimicrobial compounds used.
Table 2. Source and main characteristics of the antimicrobials explored. Both administration patterns and withdrawal
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3.1.2. Collection of Urine Samples Containing In Vivo Injected Antibiotics
A total of 66 previously untreated piglets were procured at treatment onset. Starting
at 40 days before administration of the compounds, they were kept on the premises of the
Faculty of Veterinary Sciences at the University of Zaragoza (Zaragoza, Spain) and used
in tandem for another study [54]. Pigs were provided by a commercial farm (Valporgen
S.L., Zaragoza, Spain), their genetics were Landrace × Large White, and they weighed an
average of 44.9 ± 4.8 kg at reception. From them, 39 were female and 27, male. During
acclimatization and withdrawal periods, the piglets were fed ad libitum with a special mixed
feed free of antibiotics (ARS Alendi S.A., Huesca, Spain), and water was provided from a
separate, controlled water circuit. Piglets were raised in separate pens depending on the
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antibiotic with which they were administrated. Table 2 summarizes the main characteristics
of the treatments carried out with each antimicrobial.
Overall, 4 pigs remained untreated as blank sample references, and 62 pigs were
treated: 20 were administered with sulfamethoxypyridazine, 20 with oxytetracycline, and
22 with enrofloxacin. Urine was collected on different days within the withdrawal period
determined by the respective antimicrobial drug manufacturers. It was collected from
live pigs via mobilization of the animal and bladder stimulation. At pre-set time intervals,
pigs were slaughtered and urine was obtained via bladder puncture; at the same time,
urine was gathered from living animals subjected to the same treatment and withdrawal
period. Consequently, urine was collected from 1 to 9 pigs on each day of analysis. As
animals were bred in batches and slaughtered all along the withdrawal period, the number
of sampled animals decreased as the withdrawal period progressed. Samples were kept
aliquoted and frozen at −20 ◦C until analysis.
3.1.3. Ethical Approval
The study was carried out in accordance with the ARRIVE (Animal Research: Report-
ing of In Vivo Experiments) initiative and approved by the Animal Ethics Experimentation
Committee of the University of Zaragoza (PI58/17). Animals were handled and used in
accordance with the Spanish Animal Protection Policy RD 53/2013 [71], which complies
with the European Union Directive 2010/63 [72] on the protection of animals used for
experimental and other scientific purposes.
3.2. LC-MS/MS Analysis
3.2.1. Standards and Reagents
LC-MS/MS grade solvents were from Fisher Chemical (Fisher Scientific, Leics, UK).
Formic acid (98–100%) was from Fisher Chemical (Fisher Scientific, Geel, Belgium). Puri-
fied water was obtained through a Milli-Q system (Millipore, Merck KGaA, Darmstadt,
Germany). Ciprofloxacin, enrofloxacin, oxytetracycline, and sulfamethoxypyridazine, as
well as internal standard (IS) demeclocycline, were made by Vetranal (Sigma-Aldrich AG,
Buchs, Switzerland). Enrofloxacin-d8 and sulfamethoxypyridazine-d3 were purchased
from Witega (Witega, Berlin, Germany). For the preparation of 0.1 M EDTA, 3.72 g of EDTA
Na2·H2O (>98%, Sigma-Aldrich Chemie, Steinheim, Germany) were dissolved and mixed
with up to 100 mL of distilled water.
Stock solutions (1 mg mL−1) for each standard were prepared in methanol and kept
at −20 ◦C. Spiking solution contained each of the studied analytes at 0.6 µg mL−1, and
IS spiking solution contained 1.2 µg mL−1 of each IS. Both solutions were prepared in
methanol and maintained at −20 ◦C.
3.2.2. Sample Preparation
1.5 mL of urine were spiked with 100 µL of IS spiking solution. 100 µL 0.1M EDTA
and 5 mL of purified water were added and mixed. 500 µL were taken and further diluted
with 1500 µL of purified water. It was filtered through 0.2 µm directly into HPLC vials.
3.2.3. LC-MS/MS Determination
All urine samples were analysed using a SCIEX Exion LC coupled to a TripleQuad
6500+ triple quadrupole detector equipped with an Acquity UPLC® BEH C18 column
(1.7 µm, 2.1 × 100 mm). The mobile phase consisted of eluent A (0.1% formic acid in
water) and eluent B (0.1% formic acid in acetonitrile) at a flow rate of 0.4 mL min−1. The
gradient started at 5%B, increased at a constant rate until 40%B in 3.75 min, then increased
in a second ramp until 95%B in 4.37 min, held constant until 5.00 min, then returned to
the initial 5% and held constant until 7.00 min. The injected volume was 5 µL. Positive
electrospray ionisation was used, and analytes were detected in MRM mode by monitoring
2 transitions for each compound of interest (Table 3). Regardless of the compound analysed,
the technique’s limit of detection (LoD) was 10 ppb.
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Table 3. Monitored ions via LC-MS/MS ESI+ in MRM mode.
Compound Precursor Product 1 DP (V) 2 CE (V)
Enrofloxacin
360 342 72 30
266 72 50
Ciprofloxacin 332 314 61 30
231 61 50
Ciprofloxacin-D8 (IS) 340 322 61 30
Sulfamethoxypyridazine 281 156 60 25
108 60 35
Sulfamethoxypyridazine-D3 (IS) 284 156 60 25
Oxytetracycline 461 426 65 30
Demeclocycline (IS) 443 65 17
465 154 65 40
1 DP: declustering potential; 2 CE: collision energy.
3.3. Pharmacokinetic Parameters and Statistical Analysis
For each day of the withdrawal period pre-set in this study to evaluate the behaviour
of antimicrobials, 1 to 9 samples of urine coming from different animals subjected to
the same treatment and withdrawal period were analysed via LC-MS/MS. Results were
represented as the mean ± standard deviation using the PRISM® program (GraphPad
Software, Inc., San Diego, CA, USA).
The rates of elimination (λz) of antibiotics from urine were determined via regression
analysis. The corresponding half-lives of elimination(T1/2) were calculated according to the
following equation:
Equation (1): Half-life of elimination where T1/2 is the half-life of elimination and λZ





Data obtained were analysed and submitted to comparison of averages via ANOVA,
followed by a post hoc Tukey test and t-tests with GraphPad PRISM®. Differences were
considered significant if p < 0.05.
4. Conclusions
Most of the antibiotics commonly used in chemotherapy are removed from animals´
bodies via urine, thereby contaminating farm wastes, which, if not properly treated, might
reach the surroundings, contributing to the dissemination of AMR. To avoid this, a good
choice of antimicrobial compound for therapy is required, along with accurate waste
management. The study of three widely used antimicrobials showed high excretion rates
via urine. This finding has great potential in terms of antibiotic control on the farm
level, although it necessarily requires that producers perform slurry purification. Sul-
famethoxypyridazine proved to be rapidly excreted by urine (a half-life time of 0.49 days)
and enrofloxacin had an intermediate rate of removal by urine (1.48 days); conversely,
oxytetracycline took much longer (4.18 days). Hence, after the study of these compounds’
removal rates, at equal susceptibility of the target microorganism, sulfamethoxypyridazine
would be the treatment of choice, proving that an in-depth study of the excretion pathways
of antimicrobials used in farms will help farmers and producers to choose the most appro-
priate one in order to optimize waste management and avoid the emergence of AMR while
preserving the global One Health approach.
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